Medicines Manufacturing Innovation Centre
The Medicines Manufacturing Innovation Centre (MMIC) is a collaboration between CPI (Centre for Process Innovation), University of Strathclyde, UK Research and Innovation, Scottish Enterprise and founding industry partners, AstraZeneca and GlaxoSmithKline.
The new centre is being constructed in the Advanced Manufacturing Innovation District Scotland business park and will be an international beacon for innovation in small molecule medicines manufacturing. The state-of-the-art facilities will enable collaborative working to be achieved between healthcare providers, regulators, industry and academics on technology to accelerate and improve the medicines supply chain.
The MMIC aims to deliver a series of ‘grand challenges’ that are currently faced by the pharmaceutical industry. Grand challenges one and two are already under way, with challenge one redefining how solid dosage medicines are produced, and challenge two examining how clinical supply material can be delivered using a modular robotics system.
Launched in 2018, construction is scheduled for completion in late 2021, with Currie & Brown engaged to provide project management, cost management and clerk of works services through design and construction.
The two-storey, steel-framed building will cover approximately 6,500m2 of space on piled foundations. The ground floor will provide an office and reception area, alongside four cleanrooms which will be GMP (good manufacturing practice) compliant with associated materials and people air-locks to facilitate the MMIC’s ‘grand challenge’ programmes.
On the first floor there will be an events space for pharmaceutical sector-focused activities, meeting rooms, breakout areas and supporting facilities. Walk-on ceilings will provide access to the cleanroom utilities. The project aims to achieve BREEAM ‘Very Good’ status as a minimum.